Novo Nordisk opens Capital Markets Day with semaglutide at 75% of sales
Morgan Stanley estimates semaglutide will generate three-quarters of 2026 revenue, leaving the pipeline central to the company's valuation.
The wire
- 01Novo Nordisk opens its London Capital Markets Day Monday after reporting DKK 78.49 billion adjusted Q2 sales, up 7% at constant rates, with adjusted operating profit up 11% to DKK 33.39 billion.
- 02August guidance still allows adjusted sales and operating profit to fall 6% at constant rates, and management said lower realised prices diluted 16% obesity-care volume growth.
- 03The company reported 265,000 weekly US Wegovy pill prescriptions as of July 17; third-quarter results follow November 4, and analyst targets span $40 to $73.50.
From the source
Read at ts2.techNovo Nordisk Stock at $43.24 Faces a Semaglutide Strategy Test
Novo Nordisk A/S (NYSE:NVO; CPH:NOVO-B) will open its Capital Markets Day in London on Monday. Its U.S. shares closed Friday at $43.24, up 0.12%.